NCT03778424Available不适用
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- Eisai Inc.
- 试验地点
- 3
研究概览
简要总结
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 4 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.
排除标准
- •Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
不适用
An Extended Access Program (EAP) for PerampanelPrimary Generalized Tonic-Clonic or Partial Onset SeizuresLennox Gastaut SyndromeNCT02307578Eisai Inc.
No Longer Available
不适用
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung CancerNCT03503890AbbVie
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
Available
不适用
Intermediate-Size Expanded Access Protocol (EAP) for LP352NCT06149663Longboard Pharmaceuticals
No Longer Available
不适用
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)NCT04278235AbbVie